{
    "clinical_study": {
        "@rank": "152997", 
        "arm_group": {
            "arm_group_label": "Treatment arm", 
            "arm_group_type": "Experimental", 
            "description": "All participants will be enrolled on to one, open-label arm. Participants will be treated with valproic acid in addition to standard of care therapy."
        }, 
        "brief_summary": {
            "textblock": "The study investigates valproic acid added to radiation and temozolomide therapy (standard\n      of care) for progressive or recurrent pediatric brain tumors."
        }, 
        "brief_title": "Valproic Acid in Childhood Progressive Brain Tumors", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Pediatric Brain Tumor", 
            "Glioma", 
            "Anaplastic Astrocytoma", 
            "Medulloblastoma", 
            "Glioblastoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Astrocytoma", 
                "Brain Neoplasms", 
                "Glioblastoma", 
                "Glioma", 
                "Medulloblastoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with progressive or recurrent pediatric brain tumors are administered valproic\n      acid, an HDAC inhibitor, along with standard of care therapy (radiation and temozolomide)\n      for induction therapy. Thereafter, patients will be able to continue on valproic acid and\n      temozolomide therapy as long as the combination is well tolerated and the tumor is not\n      progressing."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject, parent, or guardian willing and able to give informed consent\n\n          -  Recurrent or progressive pediatric brain tumor, with MRI evidence of disease\n\n          -  Age at first diagnosis of brain tumor 1-21 years old\n\n          -  Lansky or Karnofsky performance score of at least 50 at diagnosis\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  Prior intolerance to valproic acid\n\n          -  History of use of temozolomide\n\n          -  Use of enzyme inducing anticonvulsant medications (see appendix B)\n\n          -  Known urea cycle disorder (e.g. ornithine transcarbamylase deficiency)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01861990", 
            "org_study_id": "VA2013", 
            "secondary_id": "IRG-97-219-14"
        }, 
        "intervention": {
            "arm_group_label": "Treatment arm", 
            "description": "All participants enrolled on valproic acid arm.", 
            "intervention_name": "Valproic Acid", 
            "intervention_type": "Drug", 
            "other_name": "Valproate, VPA, Depakote, Depakote ER, Depakene"
        }, 
        "intervention_browse": {
            "mesh_term": "Valproic Acid"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Glioma", 
            "Glioblastoma", 
            "Pediatric", 
            "Child", 
            "Brain tumor", 
            "Astrocytoma", 
            "Medulloblastoma", 
            "PNET"
        ], 
        "lastchanged_date": "January 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Charleston", 
                    "country": "United States", 
                    "state": "South Carolina", 
                    "zip": "29425"
                }, 
                "name": "Medical University of South Carolina"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Valproic Acid for Children With Recurrent and Progressive Brain Tumors", 
        "overall_official": {
            "affiliation": "MUSC", 
            "last_name": "Amy L Bredlau, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Data and Safety Monitoring Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Number of participants completing the protocol will be measured.", 
            "measure": "Completion of protocol", 
            "safety_issue": "Yes", 
            "time_frame": "2 months"
        }, 
        "reference": [
            {
                "PMID": "22037799", 
                "citation": "Van Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MV, Sminia P, Stalpers LJ. Valproic acid sensitizes human glioma cells for temozolomide and \u03b3-radiation. J Neurooncol. 2012 Mar;107(1):61-7. doi: 10.1007/s11060-011-0725-z. Epub 2011 Oct 26."
            }, 
            {
                "PMID": "22753697", 
                "citation": "Asklund T, Kvarnbrink S, Holmlund C, Wibom C, Bergenheim T, Henriksson R, Hedman H. Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors. Anticancer Res. 2012 Jul;32(7):2407-13."
            }, 
            {
                "PMID": "20308311", 
                "citation": "Fu J, Shao CJ, Chen FR, Ng HK, Chen ZP. Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro Oncol. 2010 Apr;12(4):328-40. doi: 10.1093/neuonc/nop005. Epub 2009 Oct 15."
            }, 
            {
                "PMID": "21880994", 
                "citation": "Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011 Sep 20;77(12):1156-64. doi: 10.1212/WNL.0b013e31822f02e1. Epub 2011 Aug 31."
            }, 
            {
                "PMID": "18751431", 
                "citation": "Masoudi A, Elopre M, Amini E, Nagel ME, Ater JL, Gopalakrishnan V, Wolff JE. Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res. 2008 Jul-Aug;28(4C):2437-42."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01861990"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of South Carolina", 
            "investigator_full_name": "Amy-Lee Bredlau", 
            "investigator_title": "Director, Pediatric Brain Tumor Program", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Participants will be evaluated for progression every 2 months while on the study.", 
            "measure": "Time to progression", 
            "safety_issue": "No", 
            "time_frame": "2 months"
        }, 
        "source": "Medical University of South Carolina", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of South Carolina", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014", 
        "why_stopped": "Feasibility of the trial was proven to be absent."
    }
}